Considerations for the Assessment of COVID-19 Vaccines for Listing by WHO

Overview
This document provides advice to manufacturers on both the process and the criteria that will be used by the World Health Organization (WHO) to evaluate COVID-19 vaccines that are submitted either for prequalification (PQ) or for Emergency Use Listing (EUL). The current status of development of a candidate Covid-19 vaccine, the extent of the available quality, safety and efficacy data and regulatory approvals by relevant NRAs will guide WHO’s decision on which pathway (PQ or EUL) to follow for each vaccine.
The submission and review processes are described. Only vaccines that have undergone phase IIb or phase III studies and have received authorization from a reference NRA should be submitted for consideration. Criteria that will be used to assess clinical trial design, endpoints, and statistical criteria are described. Specific data that should be submitted to answer programmatically relevant questions are outlined. Manufacturing, quality control and labelling requirements are summarized, as are non-clinical data to address the potential for vaccine-associated enhanced disease. Post-authorization commitments are specified.
This document should be read in conjunction with the following:
Procedure for assessing the acceptability, in principle, of vaccines for purchase by United Nations agencies
WHO Technical Report Series 978, Annex 6, 2013
Guidelines on clinical evaluation of vaccines: regulatory expectations
WHO Technical Report Series 1004, Annex 9, 2017
COVAX SAGE Compendium of Covid-19 vaccine research questions
Points to Consider for assuring the quality, safety and efficacy of RNA vaccines
(currently under development)
WHO guidelines on nonclinical evaluation of vaccines. TRS 927, Annex 1
Guidelines on the nonclinical evaluation of vaccine adjuvants and adjuvanted vaccines
Recommendations for the Evaluation of Animal Cell Cultures as Substrates for the Manufacture of Biological Medicinal Products and for the Characterization of Cell banks
WHO Technical Report Series 978, Annex 3, 2013
WHO good manufacturing practices for biological products